Loading...
•
Jun 30, 2021
Omeros Q2 2021 Earnings Report
Omeros reported an increase in OMIDRIA revenues and a net loss for the second quarter of 2021.
Key Takeaways
Omeros Corporation reported financial results for the second quarter ended June 30, 2021. OMIDRIA revenues increased compared to the first quarter. The company's Biologics License Application (BLA) for narsoplimab is under priority review by the U.S. FDA.
OMIDRIA revenues for the second quarter of 2021 were $28.8 million, a 37% increase over the prior quarter.
Net loss in the second quarter of 2021 was $28.6 million, or $0.46 per share.
Omeros had cash, cash equivalents and short-term investments available for operations of $73.7 million as of June 30, 2021.
The FDA's action date for Omeros' BLA for narsoplimab in the treatment of HSCT-TMA is October 17, 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...